VolitionRx (NYSE-A:VNRX) Limited CEO Cameron Reynold joined Steve Darling from Proactive to share details of the company’s 2nd quarter results. Reynolds telling Proactive about CE Mark for Nu.Q NETs in Europe and also announcing new clinical studies for NETosis, or NETs, in the U.S. Reynolds also gave more details on the Volition Veterinary vertical.
VolitionRX announces 2nd quarter financials as company look to accelerate growth
